tbuckley/cabot-search huggingface dataset:
Abstract 15002: Pulse Oximetry Plethysmographic Waveform: A New Method to Identify ROSC During CPR
Authors: Chen Li, Jun Xu, Huadong Zhu, Xuezhong Yu
Journal: Circulation (2015)

Introduction: Chest compressions might not benifit the circulation in CPR when the patient got ROSC. It has been reported that pulse oximetry plethysmographic waveform (POP) reflected the peripheral tissue perfusion. We noticed that POP disappeared when the patient suffered cardiac arrest, and changed during CPR. Hypothesis: We assessed the hypothesis that the changes of POP could be utilised as a new method to identify ROSC during CPR. Methods: 617 cardiac arrest patients from 14 hospital in 10 cities were enrolled in the study. Investigate the feasibility of POP in the recognition of ROSC during CPR using time domain method and frequency domain method retrospectively. Single blind method was used in POP analysis. Results: During chest compression in cardiac arrested patients, POP in time domain showed relatively regular compression wave (Figure 1A), while frequency domain waveforms showed a single peak, with the harmonic (Figure 1B). When ROSC achieved during chest compression, POP appeared fluctuation (Figure 2A), while frequency domain waveform showed fluctuation hybrid. Integration showed a single peak spectrum (Figure 2B), while separation showed a double peak spectrum (Figure 2C). Diagnostic tests of fluctuation hybrid using frequency domain method showed Se 0.461, Sp 0.972, PV+ 0.810, PV- 0.876. Conclusions: In conclusion, POP could be used to identify ROSC during CPR.
SAT0087 Association of biometrics with disease characteristics and synovial phenotype in inflammatory arthritis
Authors: C. Low, R. Conway, F. Young, K. Murray, H. Convery, M. Biniecka, U. Fearon, D. Veale
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> The potential importance of altered body composition in the development of and disease course in inflammatory arthritis is increasingly being recognised. Body composition in different types of inflammatory arthritis and its influence on synovial pathology remains to be fully characterised. <h3>Objectives</h3> To evaluate body composition in seropositive and seronegative rheumatoid arthritis (RA) and psoriatic arthritis (PsA) patients and assess associations with disease characteristics and baseline synovial arthroscopic findings. <h3>Methods</h3> We performed a prospective observational study of consecutive inflammatory arthritis patients seen in outpatient clinics. Demographic and clinical characteristics were collected on all patients. Synovial biopsy was performed by needle arthroscopy, and macroscopic and histologic features recorded. The degree of synovitis and vascularity were recorded on a 0–100 mm visual analogue scale, and chondropathy on a semi-quantitative scale from 0–3. Mann-Whitney U test was used to compare groups. Spearman's Rank Correlation Coefficient was used to assess for associations between biometrics and demographic and clinical markers. GraphPad Prism Version 7 and IBM SPSS Statistics Version 24 were used for data analysis. <h3>Results</h3> We included 58 patients, 32 with seropositive RA, 10 with seronegative RA, and 16 with PsA. 37 (64%) were female. Mean (SD) age was 52.8 (13.9) years. Mean (SD) BMI was 29.7 (6.3) kg/m<sup>2</sup>, waist circumference was 94.4 (20.3) cm, and hip circumference 104.3 (21) cm. Full demographic and clinical details are shown in table 1. Seronegative RA patients had significantly increased BMI (p=0.033) and waist circumference (p=0.017), but not hip circumference (p=0.248) compared to seropositive RA patients. PsA patients had significantly increased BMI (p&lt;0.001), waist circumference (p=0.001), and hip circumference (p&lt;0.001) compared to seropositive but not seronegative RA patients. There was a significant correlation between waist circumference and both synovitis (r=0.31, p=0.018) and vascularity (r=0.34. p=0.010) at arthroscopy. BMI and hip circumference did not correlate with arthroscopic findings. <h3>Conclusions</h3> Different types of inflammatory arthritis have distinct body composition profiles. Waist circumference, but not other biometrics, correlates with baseline synovial inflammation and vascularity. <h3>Disclosure of Interest</h3> None declared
Significance of Soluble Interleukin-2 Receptor to Predict Prognosis and Support Decision-Making on Watchful Waiting for Stage II-IV Follicular Lymphoma Patients in the Rituximab Era
Authors: Tsuyoshi Muta, Takeshi Okatani, Mitsuhiro Itagaki, Yoshimasa Suetsugu, Masaaki Noda, Tasuya Terasaki, Yu Kochi, Fumiaki Jinnouchi, Tatsuji Mino, Ryota Imanaka, Kohei Kyo, Yuta Katayama, Shinya Katsutani, Koji Iwato, Hideki Asaoku
Journal: Blood (2018)
T- and B-Cell Neogenesis Recovers Efficiently in Children with Acute Leukemia Given an Alpha-Beta T-Cell Depleted Haplo-HSCT Followed By Infusion of Donor T-Cells Genetically Modified with Inducible Caspase 9 Suicide Gene (BPX-501 cells)
Authors: Marialuigia Catanoso, Emmanuel Clave, Corinne Douay, Mattia Algeri, Isabelle Fournier, Valentina Bertaina, Itaua Leston Araujo, Francesca Del Bufalo, Federica Galaverna, Cecilia Surace, Alice Bertaina, Pietro Merli, Aaron Foster, Antoine Toubert, Franco Locatelli
Journal: Blood (2018)
Unraveling the Landscape of Copy Number Aberrations in Hodgkin Lymphoma: A Joint KU Leuven and Lysa Study on Circulating Cell Free DNA
Authors: Lieselot Buedts, Luc Mathieu Fornecker, Julio Finalet-Ferreiro, Luc Dehaspe, Thomas Tousseyn, Olivier Gheysens, Julien Lazarovici, Rene-Olivier Casasnovas, Christiane Copie, Gregor Verhoef, Sanne Smits, Joris Vermeesch, Marc Andre, Peter Vandenberghe
Journal: Blood (2018)
AB1478-HPR Promoting exercise in rheumatic diseases: physical therapists’ understanding
Authors: E Swärdh, C. Opava, L. Nygård, I. Lindquist
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Physical therapists have unique expertise in planning, prescribing and supporting exercise programs for patients with chronic diseases. Promoting exercise can be a challenge and include a range of strategies, but descriptions of physical therapists' experiences within the field of rheumatology are limited. <h3>Objectives</h3> The purpose of this study was to explore and describe ways of understanding exercise promotion among physical therapists working with patients having rheumatic diseases. <h3>Methods</h3> A phenomenographic approach was used to analyse semi-structured interviews with 25 physical therapists, working primarily within the field of rheumatology, from eight different physical therapy departments at hospitals in various cities of Sweden. <h3>Results</h3> Four categories related to the promotion of exercise were identified: <i>to tell and monitor; to identify and pilot; to discuss and enable;</i> and<i> to listen and inspire.</i> Key aspects were responsibility, setting and supervision, tools to support change and the role as an educator. The findings are interpreted as a hierarchically organised structure, where the understandings of the PTs differ in respect to comprehensiveness regarding some aspects of interaction and collaboration with the patients. <h3>Conclusions</h3> Physical therapists working with patients having rheumatic diseases understand exercise promotion in different ways and these understandings differ in respect to comprehensiveness, which might lead to unequal promotion. A more comprehensive repertoire would probably make physical therapists more prepared to meet patients' needs for different strategies in the adoption and maintenance of exercise behaviours. <h3>Disclosure of Interest</h3> None declared
Menthol-modified casein nanoparticles loading 10-hydroxycamptothecin for glioma targeting therapy
Authors: Caifang Gao, Jianming Liang, Ying Zhu, Chengli Ling, Zhekang Cheng, Ruixiang Li, Jing Qin, Weigen Lu, Jianxin Wang
Journal: Acta Pharmaceutica Sinica B (2019)

Chemotherapy outcomes for the treatment of glioma remains unsatisfactory due to the inefficient drug transport across the blood-brain barrier (BBB) and insufficient drug accumulation in the tumor region. Although many approaches, including various nanosystems, have been developed to promote the distribution of chemotherapeutics in the brain tumor, the delivery efficiency and the possible damage to the normal brain function still greatly restrict the clinical application of the nanocarriers. Therefore, it is urgent and necessary to discover more safe and effective BBB penetration and glioma-targeting strategies. In the present study, menthol, one of the strongest BBB penetration enhancers screened from traditional Chinese medicine, was conjugated to casein, a natural food protein with brain targeting capability. Then the conjugate self-assembled into the nanoparticles to load anti-cancer drugs. The nanoparticles were characterized to have appropriate size, spheroid shape and high loading drug capacity. Tumor spheroid penetration experiments demonstrated that penetration ability of menthol-modified casein nanoparticles (M-CA-NP) into the tumor were much deeper than that of unmodified nanoparticles. In vivo imaging further verified that M-CA-NPs exhibited higher brain tumor distribution than unmodified nanoparticles. The median survival time of glioma-bearing mice treated with HCPT-M-CA-NPs was significantly prolonged than those treated with free HCPT or HCPT-CA-NPs. HE staining of the organs indicated the safety of the nanoparticles. Therefore, the study combined the advantages of traditional Chinese medicine strategy with modern delivery technology for brain targeting, and provide a safe and effective approach for glioma therapy.
SP0108 New approaches in measuring what matters to patients – decision aid tools
Authors: H. Bekker
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Purpose:</h3> To explain what patient decision aids are, why they help patients engage more effectively with healthcare, and how their use enables health professionals to meet clinical guidance on delivering shared decision making about treatment choices. People's healthcare decisions are emotionally and cognitively demanding, involving trade-offs between treatment options with negative consequences for themselves and their families. Health professionals are delivering increasingly complex care; patients live longer with co-morbidities and increased frailty, and new technologies lead to more treatments being offered. Decision science provides insight into how people make these decisions, and what can influence people's thinking encouraging them to make more or less reasoned choices. Patient decision aids are resources developed with reference to decision science evidence on how to structure the health problem, present information about risks, benefits and consequences of options, elicit patient values and guide people to reach treatment choices that fit best in their lives (http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD001431.pub5/full). This talk provides an overview of the components within patient decision aids (http://ipdas.ohri.ca/who.html) known to support people make more reasoned decisions about their healthcare, using examples taken from patient decision aids developed and evaluated within the UK. <h3>Disclosure of Interest</h3> None declared
Center Size and Glycemic Control: An International Study With 504 Centers From Seven Countries
Authors: Niels H. Birkebaek, Julia M. Hermann, Lena Hanberger, Dimitrios Charalampopoulos, Reinhard W. Holl, Torild Skrivarhaug, Karin Aakesson, Justin T. Warner, Ann K. Drivvoll, Ann-Marie Svensson, Terence Stephenson, Sabine E. Hofer, Siri Fredheim, Siv J. Kummernes, Rakesh Amin, Birgit Rami-Merhar, Anders Johansen, Thomas M. Kapellen, Doerte Hilgard, Knut Dahl-Jørgensen, Elke Froehlich-Reiterer, Maria Fritsch, Ragnar Hanas, Jannet Svensson
Journal: Diabetes Care (2019)

The variance in glycemic control between different childhood diabetes centers is not fully understood. Although the International Society for Pediatric and Adolescent Diabetes guidelines from 2014 recommended center sizes of more than 150 patients (1), it has not been thoroughly investigated whether glycemic control is associated with center size (2–4). We have data from more than 500 childhood diabetes centers from seven different countries and thereby a unique opportunity to elaborate further on this association. Therefore, this study aims to investigate the relationship between center size and glycemic control in children with type 1 diabetes (T1D).

Patient data have been described previously (5). Briefly, the population comprised children with T1D in the age-group  3 months from seven high-income countries during 2013–2014: Austria, Denmark, England, Germany, Norway, Sweden, and Wales. Data were anonymized and obtained from five national registries/audits on children with T1D (Austria and Germany use the same electronic health record and England and Wales have a common National Paediatric Diabetes Audit, while Denmark, Norway, and Sweden have national registries). Mean HbA1c was compared between groups after adjusting for sex, age (<6 years, 6 to <12 years, and 12–18 years), duration of diabetes (<2 years, 2 to <5 years, and ≥5 years), and minority status (yes/no) (HbA1c adj) before and after stratifying for treatment modality (insulin injection/pump). Center size was defined as the number of patients with diabetes reported to be cared for in a center. Center size groupings were 1 …
FRI0201 Healthy individuals at increased risk for axial spondyloarthritis would consider using medication in a preventive setting
Authors: J.J. de Winter, H.M. De Jong, P.T. Nieuwkerk, I.E. van der Horst-Bruinsma, D.L. Baeten, M.G. van de Sande
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Axial spondyloarthritis (axSpA) is a chronic inflammatory disease with a diagnostic delay of 5–10 years. Treating the disease in the pre-clinical phase before the disease becomes clinically manifest is not yet clinical practice, although initiatives to diagnose axSpA in an early phase such as the SPondyloArthritis Caught Early (SPACE) cohort and the pre-SpA cohort might enable early or even pre-clinical detection and thus treatment of SpA. Possibly, very early treatment might be able to stop the disease process hereby preventing the development of irreversible structural damage or, ideally, even disease onset. <h3>Objectives</h3> To study the willingness of individuals with an increased risk for SpA to use medication in a preventive setting. <h3>Methods</h3> Healthy first degree relatives of HLA-B27 positive axSpA patients from the Pre-SpA cohort completed a questionnaire consisting of different hypothetical scenarios varying in 1) the risk of developing axSpA, 2) the occurrence and nature of possible side effects, and 3) the effectiveness of the medication. Moreover, the survey included multiple choice questions about participants' perception towards SpA and preventive medication. <h3>Results</h3> The response rate was 81.5% (106 out of 130). Figure 1 shows the comparison of the different scenarios. The percentage of individuals willing to use preventive medication causing no side effects varied between 63.2% (with 30% SpA risk) and 91.5% (with 70% SpA risk). The percentage of individuals willing to use this medication varied between 27.4% (with 30% SpA risk) and 51.9% (with 70% SpA risk) if the preventive medication would possibly cause infections. This percentage was 32.1% (with 30% SpA risk) if the medication would possibly cause mild side effects. The percentage of individuals willing to use preventive medication that would cause a delay in onset of SpA of 10 years (with 70% SpA risk) was 72%. The willingness of individuals to use preventive medication was negatively influenced by their own risk assessment of developing SpA (B=0.16, p=0.001) and was not primarily influenced by costs (0.9%) or the route of administration (0%). <h3>Conclusions</h3> 1. Individuals at increased risk for SpA would consider using preventive medication. 2. Their willingness to use preventive medication is largely influenced by the formal likelihood to develop SpA, by their own perception of the disease and by the likelihood of side effects. 3. Their willingness to use preventive medication is not primarily influenced by costs and the route of administration. <h3>Disclosure of Interest</h3> None declared
Long-Term Efficacy and Safety of Recombinant Interferon Alpha-2 Vs. Hydroxyurea in Polycythemia Vera: Preliminary Results from the Three-Year Analysis of the Daliah Trial - a Randomized Controlled Phase III Clinical Trial
Authors: Trine Alma Knudsen, Dennis Lund Hansen, Lukas Frans Ocias, Ole Weis Bjerrum, Mette Brabrand, Daniel El Fassi, Mikael Frederiksen, Lasse Kjær, Thomas Kielsgaard Kristensen, Torben A Kruse, Torben Mourits-Andersen, Peter Møller, Ulrik Malthe Overgaard, Marianne Tang Severinsen, Vibe Skov, Jesper Stentoft, Jørn Starklint, Karin de Stricker, Mads Thomassen, Thomas Stauffer Larsen, Hans Carl Hasselbalch
Journal: Blood (2018)
Complication Rates and Downstream Medical Costs Associated With Invasive Diagnostic Procedures for Lung Abnormalities in the Community Setting
Authors: Jinhai Huo, Ying Xu, Tommy Sheu, Robert J. Volk, Ya-Chen Tina Shih
Journal: JAMA Internal Medicine (2019)

IMPORTANCEThe Centers for Medicare & Medicaid Services added lung cancer screening with low-dose computed tomography (LDCT) as a Medicare preventive service benefit in 2015 following findings from the National Lung Screening Trial (NLST) that showed a 16% reduction in lung cancer mortality associated with LDCT.A challenge in developing and promoting a national lung cancer screening program is the high false-positive rate of LDCT because abnormal findings from thoracic imaging often trigger subsequent invasive diagnostic procedures and could lead to postprocedural complications.OBJECTIVE To determine the complication rates and downstream medical costs associated with invasive diagnostic procedures performed for identification of lung abnormalities in the community setting. DESIGN, SETTING, AND PARTICIPANTSA retrospective cohort study of non-protocol-driven community practices captured in MarketScan Commercial Claims & Encounters and Medicare supplemental databases was conducted.A nationally representative sample of 344 510 patients aged 55 to 77 years who underwent invasive diagnostic procedures between 2008 and 2013 was included. MAIN OUTCOMES AND MEASURESOne-year complication rates were calculated for 4 groups of invasive diagnostic procedures.The complication rates and costs were further stratified by age group. RESULTSOf the 344 510 individuals aged 55 to 77 years included in the study, 174 702 comprised the study group (109 363 [62.6%] women) and 169 808 served as the control group (106 007 [62.4%] women).The estimated complication rate was 22.2% (95% CI, 21.7%-22.7%)for individuals in the young age group and 23.8% (95% CI, 23.0%-24.6%)for those in the Medicare group; the rates were approximately twice as high as those reported in the NLST (9.8% and 8.5%, respectively).The mean incremental complication costs were $6320 (95% CI, $5863-$6777) for minor complications to $56 845 (95% CI, $47 953-$65 737) for major complications. CONCLUSIONS AND RELEVANCEThe rates of complications after invasive diagnostic procedures were higher than the rates reported in clinical trials.Physicians and patients should be aware of the potential risks of subsequent adverse events and their high downstream costs in the shared decision-making process.
Clinical Efficacy of Intracellular Molecular Inhibitors for Relapsed, Refractory Multiple Myeloma: A Systematic Review of Early Clinical Data
Authors: Shehroz Aslam, Mustafa Nadeem Malik, Abdul Rafae, Rida Riaz, Muhammad Jahanzeb Khalil, Faisal Mahfooz, Madeeha Shafqat, Anum Qureshi, Insija Ilyas Selene, Syed Shabee Hassan, Muhammad Junaid Tariq, Muhammad Yasir, Sharoon Samuel, Maryam Sadiq, Faiz Anwer
Journal: Blood (2018)
AB0013 Expression levels of mir-124 in the plasma of rheumatoid arthritis patients
Authors: R. Shumnalieva, D. Kachakova, V. Shoumnalieva–Ivanova, P. Miteva, R. Kaneva, Z. Kolarov, S. Monov
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Micro-ribonucleic acids (microRNAs) comprise a class of small non-coding RNAs that regulate gene expression on post transcriptional level. Levels of miR-124 have been found to be decreased in rheumatoid arthritis (RA) synoviocytes and <i>in vivo</i> studies have shown that treatment with pre-miR-124 suppresses the progression of joint damage<sup>1</sup>. <h3>Objectives</h3> To evaluate the expression levels of miR-124–3 p in plasma of RA patients and to determine its possible role as biomarker for diagnosis and disease activity. <h3>Methods</h3> 34 RA patients according to the 1987 ACR criteria were included in the study. Expression levels of miR-124–3 p in the plasma were determined by PCR (SYBR Green technology). 2<sup>-ΔΔCt</sup> method was used for analysis. 10 healthy donors were used as controls. <h3>Results</h3> Expression levels of miR-124–3 p were upregulated in the plasma of 33 (97.06%) of the patients when compared to controls. Receiver operating characteristic curve analysis was conducted in order to evaluate the diagnostic accuracy of the expression levels of the studied miRNA in the plasma. Area under the curve for miR-124–3 p was 0.879 (95% CI=0.740–1.00), p=0.303 × 10–3. When the relative quantification (RQ) cut value was 2.89, the sensitivity was 91.2% and the specificity was 80%. Levels of miR-124–3 p in plasma correlated with the diagnosis (p=0.106 × 10–3), with markers of inflammation – ESR (p=0.0497) and CRP (p=0.047) as well as with the immunological activity – the presence of RF (p=0.007), RF IgM (p=0.004), RF IgG (p=0.004), RF IgA (p=0.005) and anti-CCP antibodies in the serum (p=0.025). <h3>Conclusions</h3> In contrary to the literature data that report levels of miR-124 to be decreased in RA synovial fibroblasts we found increased expression of miR-124–3 p in the plasma of RA patients which might reflect the pathophysiological response to the inflammation, the effect of the treatment regimen or the presence of miR-124a gene promotor hypermethylation in the synovial tissue which might downregulate miR-124 locally.<sup>1 2</sup> To our knowledge this is the first study to evaluate the diagnostic accuracy of plasma levels of miR-124 in RA patients as well as the possibility of using miR-124 as biomarker for disease activity but larger set is needed to confirm these results in the clinical practice. <h3>References</h3> [1] Nakamachi Y, et al. MicroRNA-124a is a key regulator of proliferation and monocyte chemoattractant protein 1 secretion in fibroblast-like synoviocytes from patients with rheumatoid arthritis, Arthritis Rheum2009;60(5):1294–1304. [2] Zhou Q, et al. Research of the Methylation Status of miR-124a Gene Promoter among Rheumatoid Arthritis Patients. Clin Dev Immunol2013(2013):524204. <h3>Acknowledgements</h3> The study was supported by Grant 76/2016 funded by Medical University – Sofia, Bulgaria. <h3>Disclosure of Interest</h3> None declared
Knockout of CBLB Greatly Enhances Anti-Tumor Activity of CAR T Cells
Authors: Kathryn Hooper, Kyle Havens, Anne-Rachel Krostag, Michael S Magee, Unja Martin, Ankit Gupta, Yegor Smurnyy, Lisa Pechilis, Amanda Rode, Andrew Chavkin, Shannon Grande, Richard A. Morgan, Jordan Jarjour, Alexander Astrakhan
Journal: Blood (2018)